CA2191440C - Traitement et prevention d'infections causees par les bacteries du genre helicobacter - Google Patents
Traitement et prevention d'infections causees par les bacteries du genre helicobacter Download PDFInfo
- Publication number
- CA2191440C CA2191440C CA002191440A CA2191440A CA2191440C CA 2191440 C CA2191440 C CA 2191440C CA 002191440 A CA002191440 A CA 002191440A CA 2191440 A CA2191440 A CA 2191440A CA 2191440 C CA2191440 C CA 2191440C
- Authority
- CA
- Canada
- Prior art keywords
- helicobacter
- catalase
- vaccine composition
- prevention
- infection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000002265 prevention Effects 0.000 title claims abstract description 26
- 206010019375 Helicobacter infections Diseases 0.000 title claims description 25
- 102000016938 Catalase Human genes 0.000 claims abstract description 57
- 108010053835 Catalase Proteins 0.000 claims abstract description 57
- 238000002360 preparation method Methods 0.000 claims abstract description 46
- 241000589989 Helicobacter Species 0.000 claims abstract description 31
- 230000000890 antigenic effect Effects 0.000 claims abstract description 21
- 230000002163 immunogen Effects 0.000 claims abstract description 20
- 239000012634 fragment Substances 0.000 claims abstract description 19
- 241000590017 Helicobacter felis Species 0.000 claims abstract 2
- 229960005486 vaccine Drugs 0.000 claims description 35
- 239000000203 mixture Substances 0.000 claims description 30
- 239000002671 adjuvant Substances 0.000 claims description 25
- 239000000427 antigen Substances 0.000 claims description 18
- 102000036639 antigens Human genes 0.000 claims description 18
- 108091007433 antigens Proteins 0.000 claims description 18
- 239000013598 vector Substances 0.000 claims description 12
- 239000003085 diluting agent Substances 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 8
- 108010046334 Urease Proteins 0.000 claims description 7
- 241000894006 Bacteria Species 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000002158 endotoxin Substances 0.000 claims description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 3
- 229920006008 lipopolysaccharide Polymers 0.000 claims description 3
- 241000588722 Escherichia Species 0.000 claims description 2
- 241000607142 Salmonella Species 0.000 claims description 2
- 241000607598 Vibrio Species 0.000 claims description 2
- 241000607734 Yersinia <bacteria> Species 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 abstract description 25
- 102000004190 Enzymes Human genes 0.000 abstract description 9
- 108090000790 Enzymes Proteins 0.000 abstract description 9
- 241000699670 Mus sp. Species 0.000 description 21
- 108090000623 proteins and genes Proteins 0.000 description 18
- 102000004169 proteins and genes Human genes 0.000 description 17
- 102000009016 Cholera Toxin Human genes 0.000 description 12
- 108010049048 Cholera Toxin Proteins 0.000 description 12
- 241000590002 Helicobacter pylori Species 0.000 description 7
- 229940037467 helicobacter pylori Drugs 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 101710194807 Protective antigen Proteins 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 5
- 239000012064 sodium phosphate buffer Substances 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 239000002033 PVDF binder Substances 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 210000001156 gastric mucosa Anatomy 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 210000004201 immune sera Anatomy 0.000 description 3
- 229940042743 immune sera Drugs 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 238000005342 ion exchange Methods 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 2
- 208000007882 Gastritis Diseases 0.000 description 2
- 208000008469 Peptic Ulcer Diseases 0.000 description 2
- 208000037581 Persistent Infection Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 230000005587 bubbling Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 208000023652 chronic gastritis Diseases 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000001024 immunotherapeutic effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229940126578 oral vaccine Drugs 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229940021993 prophylactic vaccine Drugs 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229940021747 therapeutic vaccine Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- LVSPDZAGCBEQAV-UHFFFAOYSA-N 4-chloronaphthalen-1-ol Chemical compound C1=CC=C2C(O)=CC=C(Cl)C2=C1 LVSPDZAGCBEQAV-UHFFFAOYSA-N 0.000 description 1
- 239000008001 CAPS buffer Substances 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 238000011537 Coomassie blue staining Methods 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 101100117236 Drosophila melanogaster speck gene Proteins 0.000 description 1
- 108010012253 E coli heat-labile enterotoxin Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 101900104845 Helicobacter pylori Catalase Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 244000000054 animal parasite Species 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- -1 coatings Substances 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- VVSMKOFFCAJOSC-UHFFFAOYSA-L disodium;dodecylbenzene;sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O.CCCCCCCCCCCCC1=CC=CC=C1 VVSMKOFFCAJOSC-UHFFFAOYSA-L 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 1
- 201000011587 gastric lymphoma Diseases 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920002714 polyornithine Polymers 0.000 description 1
- 108010055896 polyornithine Proteins 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000000734 protein sequencing Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
L'invention concerne une préparation antigénique utilisable pour le traitement ou la prévention des infections provoquées par les bactéries du genre Helicobacter chez les mammifères. Cette préparation comprend la catalase (enzyme) de bactéries du genre Helicobacter, en particulier la catalase de H. Pylori ou de H. Felis ou encore un fragment immunogène de celle-ci.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPM6124 | 1994-06-08 | ||
| AUPM6124A AUPM612494A0 (en) | 1994-06-08 | 1994-06-08 | Treatment or prevention of helicobacter infection |
| PCT/AU1995/000335 WO1995033482A1 (fr) | 1994-06-08 | 1995-06-08 | Traitement et prevention d'infections causees par les bacteries du genre helicobacter |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2191440A1 CA2191440A1 (fr) | 1995-12-14 |
| CA2191440C true CA2191440C (fr) | 2007-05-01 |
Family
ID=38051337
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002191440A Expired - Fee Related CA2191440C (fr) | 1994-06-08 | 1995-06-08 | Traitement et prevention d'infections causees par les bacteries du genre helicobacter |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2191440C (fr) |
-
1995
- 1995-06-08 CA CA002191440A patent/CA2191440C/fr not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2191440A1 (fr) | 1995-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0771214B1 (fr) | Traitement et prevention d'infections causees par les bacteries du genre helicobacter | |
| KR100287424B1 (ko) | 헬리코박터 감염에 대한 우레아제 기재 백신(Urease-Based Vaccine Against Helicobacter Infection) | |
| JP5327873B2 (ja) | リコンビナントヘリコバクターピロリの経口ワクチン及びその調製方法 | |
| KR0177510B1 (ko) | 에스케리키아 콜리 백신 | |
| EP0590138A1 (fr) | Traitement par voie orale de l'infection provoquee par l'helicobacter | |
| US5837825A (en) | Campylobacter jejuni flagellin/Escherichia coli LT-B fusion protein | |
| AU693864B2 (en) | Antigenic preparation for treatment or prevention of helicobacter infection | |
| JPH0811735B2 (ja) | 抗原性遺伝子ワクチン | |
| JPH11504633A (ja) | 多量体の組換えウレアーゼワクチン | |
| JP4368944B2 (ja) | 防御用ヘリコバクター抗原 | |
| KR100221452B1 (ko) | 장감염에 대한 백신조성물의 제조방법 | |
| AU702878B2 (en) | Treatment and prevention of helicobacter infection | |
| CA2191440C (fr) | Traitement et prevention d'infections causees par les bacteries du genre helicobacter | |
| Blanchard et al. | Local and systemic antibody responses in humans with Helicobacter pylori infection | |
| WO2000037106A1 (fr) | Vaccin oral contre la diarrhee | |
| JP2001523954A (ja) | ７６ ｋＤａ、３２ ｋＤａ、および５０ ｋＤａヘリコバクター（Ｈｅｌｉｃｏｂａｃｔｅｒ）ポリペプチドおよび対応するポリヌクレオチド分子 | |
| CA2813040C (fr) | Proteines coregulees secretees par campylobacter flagella en tant qu'immunogenes | |
| WO1998006853A1 (fr) | Traitement et prevention des infections a helicobacter | |
| EP0255755A2 (fr) | Préparation de vaccin | |
| CN119343364A (zh) | 钩端螺旋体病疫苗 | |
| Pandher | Molecular and immunological analyses of 38 kDA and 45 kDA protein antigens of Pasteurella haemolytica S1 | |
| Moore | crja4/^ Yf _ | |
| Osato et al. | B-Cell and T-Cell Immune Responses to |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |